Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
Holding ARGX?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$1.22Last Year’s EPS
-$1.68Same Quarter Last Year
Strong Buy
Based on 23 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2024
|% Change Since: 13.07%
|Next Earnings Date:Feb 27, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong financial performance with record-breaking revenue growth and successful product launches, particularly in the CIDP segment. However, challenges such as increased operating expenses and the discontinuation of efgartigimod in MN slightly offset the positive aspects. Overall, the company shows strong momentum and a solid financial position.Company Guidance
During the Q3 2024 earnings call for ARGX.BR, the company provided robust guidance and metrics reflecting their strategic advancements and financial performance. Argenx reported total operating income of $589 million, with $573 million from product net sales, marking a 20% quarter-over-quarter growth and a 74% increase compared to the prior year. The company's cash balance stood at $3.4 billion, and the financial guidance for combined SG&A and R&D spend of $2 billion remained unchanged. In CIDP, over 300 patients commenced treatment by the quarter's end, contributing to revenue approaching the first MG launch quarter. The U.S. led with $492 million in sales, while Japan and China contributed $24 million and $11 million, respectively. Argenx's continued success in GMG was highlighted by the expansion of VYVGART coverage to over 80% of the GMG population in the EU, alongside a strong CIDP launch, where 85-90% of patients switched from IVIg, supporting their strategy of positioning as the leading branded biologic in MG. The company is also pursuing regulatory approvals for CIDP in China, Japan, and Europe, with decisions expected by 2025.Record-Breaking Revenue and Growth
The company reported total operating income of $589 million, representing a 20% quarter-over-quarter growth and 74% growth compared with the same quarter in the previous year.
Strong Initial CIDP Launch
CIDP launch exceeded expectations, reaching over 300 patients in the first quarter, with 85% to 90% of these patients switching from IVIG.
Continued Growth in MG Segment
MG segment showed steady growth, with Hytrulo attracting new patients and prescribers. Over 60% of new patients came from oral treatments, aligning with the strategy to reach earlier line patients.
Strong Global Presence and Expansion
VYVGART is now available to over 80% of the gMG population in the EU, and the ITP launch in Japan is showing early success with a 50% patient response rate.
Solid Financial Position
Cash balance at the end of the quarter was $3.4 billion, with an increase of EUR 272 million in the quarter. The company reported a quarterly profit after tax of $91 million.
---
ARGX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ARGX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $551.71 | $586.30 | +6.27% |
| Jul 25, 2024 | $464.36 | $486.33 | +4.73% |
| May 09, 2024 | $386.08 | $382.55 | -0.91% |
| Feb 29, 2024 | $397.70 | $380.01 | -4.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Argenx Se (ARGX) report earnings?
Argenx Se (ARGX) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is Argenx Se (ARGX) earnings time?
Argenx Se (ARGX) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARGX EPS forecast?
ARGX EPS forecast for the fiscal quarter 2024 (Q4) is $1.22.
---